Showing results (501-510 of 757) with videos related to
Sort By:
Pageof 76
Diabetes Care|December 6, 2017
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Bernard Zinman, David Fitchett, et al.Journal of the American Society of Nephrology : JASN|February 9, 2007
Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout miceThomas Quaschning, Florian Voss, Katharina Relle, et al.Clinical Journal of the American Society of Nephrology : CJASN|October 24, 2008
OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patientsJoel D Kopple, Alfred K Cheung, Jens Sandahl Christiansen, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 29, 2014
Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA RegistryElke Wühl, Karlijn J van Stralen, Christoph Wanner, et al.Diabetes, Obesity & Metabolism|February 8, 2020
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOMESubodh Verma, Qiuhe Ji, Deepak L Bhatt, et al.European Heart Journal|December 8, 2022
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trialMichael Bhm, Stefan Anker, Felix Mahfoud, et al.European Journal of Heart Failure|September 16, 2025
Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-ReducedMichael Böhm, Javed Butler, Amr Abdin, et al.Clinical Journal of the American Society of Nephrology : CJASN|October 23, 2012
Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tractElke Wühl, Karlijn J van Stralen, Enrico Verrina, et al.European Journal of Heart Failure|May 25, 2021
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trialPierpaolo Pellicori, David Fitchett, Mikhail N Kosiborod, et al.Journal of the American Society of Nephrology : JASN|October 14, 2018
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME TrialChristoph Wanner, Hiddo J L Heerspink, Bernard Zinman, et al.Pageof 76